| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 99 | 2025 | 422 | 19.810 |
Why?
|
| Leukemia, Myeloid, Acute | 86 | 2026 | 824 | 10.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 72 | 2025 | 2605 | 4.760 |
Why?
|
| Antineoplastic Agents | 46 | 2025 | 2385 | 3.830 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 60 | 2025 | 942 | 3.420 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 16 | 2025 | 65 | 3.300 |
Why?
|
| Antineoplastic Agents, Immunological | 14 | 2025 | 224 | 3.170 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 9 | 2023 | 58 | 2.880 |
Why?
|
| Azacitidine | 14 | 2024 | 149 | 2.640 |
Why?
|
| Transplantation Conditioning | 40 | 2021 | 383 | 2.620 |
Why?
|
| Neoplasm, Residual | 17 | 2025 | 196 | 2.610 |
Why?
|
| Philadelphia Chromosome | 19 | 2025 | 44 | 2.550 |
Why?
|
| Young Adult | 96 | 2025 | 7026 | 2.440 |
Why?
|
| Hematologic Neoplasms | 24 | 2025 | 372 | 2.440 |
Why?
|
| Adult | 195 | 2026 | 28578 | 2.310 |
Why?
|
| Humans | 352 | 2026 | 95799 | 2.150 |
Why?
|
| Adolescent | 84 | 2025 | 9873 | 2.080 |
Why?
|
| Myelodysplastic Syndromes | 18 | 2022 | 377 | 2.070 |
Why?
|
| Mutation | 38 | 2025 | 4374 | 2.030 |
Why?
|
| Cytarabine | 25 | 2025 | 218 | 1.980 |
Why?
|
| Aged | 167 | 2026 | 20848 | 1.870 |
Why?
|
| Asparaginase | 14 | 2024 | 35 | 1.860 |
Why?
|
| Neoplasm Recurrence, Local | 27 | 2024 | 1463 | 1.740 |
Why?
|
| Remission Induction | 41 | 2025 | 750 | 1.710 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 14 | 2025 | 132 | 1.710 |
Why?
|
| Middle Aged | 176 | 2026 | 28206 | 1.700 |
Why?
|
| Treatment Outcome | 88 | 2025 | 9167 | 1.650 |
Why?
|
| Male | 192 | 2026 | 45685 | 1.520 |
Why?
|
| Leukemia | 11 | 2024 | 305 | 1.510 |
Why?
|
| Antibodies, Bispecific | 4 | 2023 | 37 | 1.500 |
Why?
|
| Leukemia, Myeloid | 10 | 2012 | 240 | 1.490 |
Why?
|
| Female | 195 | 2026 | 49869 | 1.480 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 12 | 2025 | 176 | 1.470 |
Why?
|
| Drug Resistance, Neoplasm | 24 | 2025 | 644 | 1.460 |
Why?
|
| Recurrence | 37 | 2024 | 1211 | 1.420 |
Why?
|
| Protein Kinase Inhibitors | 13 | 2023 | 611 | 1.340 |
Why?
|
| Sulfonamides | 7 | 2025 | 337 | 1.330 |
Why?
|
| Prognosis | 54 | 2025 | 3990 | 1.300 |
Why?
|
| Clinical Trials as Topic | 13 | 2026 | 1166 | 1.290 |
Why?
|
| Aged, 80 and over | 66 | 2026 | 7215 | 1.230 |
Why?
|
| Immunotherapy | 8 | 2021 | 766 | 1.180 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 5 | 2025 | 103 | 1.160 |
Why?
|
| Chromosome Aberrations | 12 | 2022 | 353 | 1.130 |
Why?
|
| Leukemia, Promyelocytic, Acute | 10 | 2022 | 48 | 1.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 21 | 2025 | 1021 | 1.100 |
Why?
|
| Alemtuzumab | 10 | 2025 | 90 | 1.090 |
Why?
|
| Molecular Targeted Therapy | 4 | 2019 | 307 | 1.080 |
Why?
|
| Disease-Free Survival | 28 | 2021 | 1194 | 1.050 |
Why?
|
| Combined Modality Therapy | 24 | 2020 | 1739 | 1.050 |
Why?
|
| Antimetabolites, Antineoplastic | 7 | 2025 | 245 | 1.030 |
Why?
|
| Transplantation, Homologous | 37 | 2021 | 1023 | 1.030 |
Why?
|
| Fusion Proteins, bcr-abl | 13 | 2025 | 110 | 1.020 |
Why?
|
| Insurance Coverage | 2 | 2025 | 144 | 1.010 |
Why?
|
| Arabinonucleosides | 5 | 2014 | 39 | 0.990 |
Why?
|
| Survival Analysis | 30 | 2024 | 1540 | 0.980 |
Why?
|
| Chemical and Drug Induced Liver Injury | 4 | 2023 | 67 | 0.960 |
Why?
|
| Age Factors | 22 | 2025 | 1957 | 0.910 |
Why?
|
| Adenine Nucleotides | 4 | 2014 | 63 | 0.900 |
Why?
|
| Acute Disease | 20 | 2023 | 859 | 0.900 |
Why?
|
| Graft vs Host Disease | 18 | 2023 | 368 | 0.890 |
Why?
|
| Medicaid | 2 | 2025 | 260 | 0.890 |
Why?
|
| Rituximab | 6 | 2024 | 132 | 0.890 |
Why?
|
| Protein-Tyrosine Kinases | 9 | 2021 | 303 | 0.870 |
Why?
|
| Survival Rate | 33 | 2024 | 1971 | 0.870 |
Why?
|
| Aniline Compounds | 2 | 2023 | 62 | 0.860 |
Why?
|
| Child | 33 | 2025 | 7618 | 0.830 |
Why?
|
| Insurance, Health | 1 | 2025 | 182 | 0.800 |
Why?
|
| Drugs, Investigational | 2 | 2017 | 38 | 0.800 |
Why?
|
| Antibodies, Monoclonal | 16 | 2018 | 1425 | 0.790 |
Why?
|
| Thrombosis | 3 | 2022 | 326 | 0.780 |
Why?
|
| Naphthyridines | 2 | 2021 | 27 | 0.780 |
Why?
|
| Salvage Therapy | 11 | 2020 | 238 | 0.780 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 7 | 2024 | 150 | 0.780 |
Why?
|
| Cord Blood Stem Cell Transplantation | 8 | 2019 | 91 | 0.760 |
Why?
|
| Vincristine | 5 | 2024 | 101 | 0.740 |
Why?
|
| Bone Marrow | 13 | 2021 | 415 | 0.740 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2016 | 107 | 0.710 |
Why?
|
| Myeloproliferative Disorders | 5 | 2024 | 144 | 0.700 |
Why?
|
| Stem Cell Transplantation | 9 | 2020 | 193 | 0.690 |
Why?
|
| Pyrimidines | 8 | 2023 | 386 | 0.650 |
Why?
|
| Polymorphism, Single Nucleotide | 11 | 2024 | 2495 | 0.650 |
Why?
|
| Daunorubicin | 9 | 2020 | 78 | 0.630 |
Why?
|
| Maximum Tolerated Dose | 12 | 2025 | 270 | 0.610 |
Why?
|
| Thromboembolism | 1 | 2020 | 128 | 0.610 |
Why?
|
| Gene Expression Regulation, Leukemic | 9 | 2025 | 99 | 0.600 |
Why?
|
| Triazoles | 3 | 2020 | 110 | 0.600 |
Why?
|
| Vidarabine | 12 | 2019 | 146 | 0.590 |
Why?
|
| Bone Marrow Transplantation | 6 | 2019 | 291 | 0.590 |
Why?
|
| Disease Management | 9 | 2025 | 360 | 0.580 |
Why?
|
| Drug Discovery | 2 | 2017 | 118 | 0.580 |
Why?
|
| Dose-Response Relationship, Drug | 18 | 2019 | 1965 | 0.580 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2020 | 43 | 0.570 |
Why?
|
| Biomarkers, Tumor | 14 | 2024 | 1670 | 0.570 |
Why?
|
| Mineralocorticoid Excess Syndrome, Apparent | 1 | 2018 | 1 | 0.570 |
Why?
|
| Hypokalemia | 1 | 2018 | 24 | 0.560 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2025 | 465 | 0.560 |
Why?
|
| Mitoxantrone | 5 | 2020 | 66 | 0.560 |
Why?
|
| Prospective Studies | 23 | 2024 | 4664 | 0.560 |
Why?
|
| High-Throughput Nucleotide Sequencing | 9 | 2025 | 540 | 0.560 |
Why?
|
| Aminopyridines | 3 | 2024 | 49 | 0.560 |
Why?
|
| Triazines | 3 | 2024 | 54 | 0.550 |
Why?
|
| Gene Deletion | 2 | 2016 | 358 | 0.550 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 4 | 2025 | 7 | 0.550 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 5 | 2025 | 207 | 0.530 |
Why?
|
| Piperazines | 6 | 2013 | 296 | 0.530 |
Why?
|
| Lymphoma, B-Cell | 3 | 2023 | 111 | 0.520 |
Why?
|
| Geriatric Assessment | 6 | 2020 | 192 | 0.520 |
Why?
|
| Risk Factors | 29 | 2023 | 5961 | 0.510 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 491 | 0.500 |
Why?
|
| Superoxide Dismutase | 2 | 2022 | 156 | 0.500 |
Why?
|
| Ikaros Transcription Factor | 2 | 2016 | 25 | 0.500 |
Why?
|
| Melphalan | 10 | 2023 | 99 | 0.500 |
Why?
|
| Thiazoles | 3 | 2014 | 130 | 0.490 |
Why?
|
| Protein Interaction Domains and Motifs | 2 | 2016 | 91 | 0.490 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 198 | 0.480 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2016 | 30 | 0.480 |
Why?
|
| Cell Line, Tumor | 11 | 2025 | 2777 | 0.480 |
Why?
|
| Lymphoma | 5 | 2025 | 253 | 0.480 |
Why?
|
| Neoplasms | 12 | 2024 | 3242 | 0.470 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2016 | 92 | 0.470 |
Why?
|
| Pharmacogenomic Variants | 1 | 2016 | 44 | 0.470 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2016 | 187 | 0.460 |
Why?
|
| SEER Program | 3 | 2025 | 235 | 0.460 |
Why?
|
| Dasatinib | 8 | 2025 | 39 | 0.460 |
Why?
|
| Methotrexate | 4 | 2022 | 232 | 0.440 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2024 | 277 | 0.440 |
Why?
|
| Consolidation Chemotherapy | 4 | 2020 | 23 | 0.440 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2021 | 325 | 0.440 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2020 | 883 | 0.440 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 52 | 0.440 |
Why?
|
| Retrospective Studies | 34 | 2026 | 10273 | 0.430 |
Why?
|
| Induction Chemotherapy | 4 | 2021 | 151 | 0.430 |
Why?
|
| United States | 13 | 2026 | 7764 | 0.430 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2024 | 62 | 0.430 |
Why?
|
| Antibodies, Neoplasm | 7 | 2010 | 86 | 0.420 |
Why?
|
| Drug Administration Schedule | 15 | 2019 | 857 | 0.410 |
Why?
|
| Histone-Lysine N-Methyltransferase | 4 | 2025 | 165 | 0.410 |
Why?
|
| Benzamides | 8 | 2025 | 248 | 0.410 |
Why?
|
| Oncogene Proteins, Fusion | 6 | 2016 | 134 | 0.400 |
Why?
|
| Pharmacogenetics | 4 | 2025 | 456 | 0.390 |
Why?
|
| Antigens, CD34 | 7 | 2017 | 163 | 0.390 |
Why?
|
| Oncologists | 3 | 2024 | 38 | 0.390 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2025 | 684 | 0.390 |
Why?
|
| Hematopoiesis | 3 | 2013 | 182 | 0.390 |
Why?
|
| CD47 Antigen | 2 | 2024 | 24 | 0.390 |
Why?
|
| Phenylurea Compounds | 2 | 2018 | 99 | 0.380 |
Why?
|
| Infant | 13 | 2025 | 3360 | 0.380 |
Why?
|
| Gene Rearrangement | 6 | 2025 | 179 | 0.380 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2014 | 396 | 0.380 |
Why?
|
| Core Binding Factors | 2 | 2011 | 12 | 0.380 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2021 | 301 | 0.380 |
Why?
|
| Quinoxalines | 2 | 2014 | 51 | 0.380 |
Why?
|
| Polyethylene Glycols | 3 | 2023 | 376 | 0.370 |
Why?
|
| Child, Preschool | 13 | 2025 | 3970 | 0.370 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 4 | 2021 | 158 | 0.370 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 4 | 2025 | 76 | 0.360 |
Why?
|
| Indazoles | 1 | 2012 | 61 | 0.360 |
Why?
|
| Mice | 17 | 2025 | 12537 | 0.340 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2016 | 1346 | 0.340 |
Why?
|
| Genetic Testing | 2 | 2018 | 565 | 0.340 |
Why?
|
| Academic Success | 2 | 2021 | 11 | 0.330 |
Why?
|
| Maintenance Chemotherapy | 4 | 2020 | 91 | 0.330 |
Why?
|
| Patient Selection | 4 | 2026 | 708 | 0.330 |
Why?
|
| Hematology | 2 | 2021 | 31 | 0.330 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 5 | 2012 | 67 | 0.320 |
Why?
|
| Transplantation, Autologous | 7 | 2019 | 361 | 0.320 |
Why?
|
| Epigenomics | 1 | 2011 | 109 | 0.320 |
Why?
|
| Retreatment | 5 | 2022 | 106 | 0.320 |
Why?
|
| Enzyme Inhibitors | 6 | 2023 | 655 | 0.310 |
Why?
|
| Hodgkin Disease | 3 | 2023 | 148 | 0.310 |
Why?
|
| Incidence | 12 | 2022 | 1714 | 0.310 |
Why?
|
| HLA Antigens | 4 | 2021 | 228 | 0.310 |
Why?
|
| Pathology, Molecular | 1 | 2009 | 34 | 0.300 |
Why?
|
| Bortezomib | 2 | 2020 | 82 | 0.300 |
Why?
|
| Clinical Decision-Making | 4 | 2020 | 296 | 0.300 |
Why?
|
| Risk Assessment | 9 | 2024 | 2480 | 0.300 |
Why?
|
| Etoposide | 7 | 2020 | 207 | 0.300 |
Why?
|
| Immunoconjugates | 2 | 2020 | 131 | 0.290 |
Why?
|
| Hepatic Veno-Occlusive Disease | 4 | 2019 | 19 | 0.290 |
Why?
|
| Apoptosis | 3 | 2025 | 1756 | 0.290 |
Why?
|
| Burkitt Lymphoma | 1 | 2009 | 34 | 0.290 |
Why?
|
| Depsipeptides | 1 | 2008 | 32 | 0.290 |
Why?
|
| Primary Myelofibrosis | 3 | 2024 | 67 | 0.280 |
Why?
|
| Animals | 21 | 2025 | 28889 | 0.280 |
Why?
|
| Thionucleotides | 5 | 2021 | 56 | 0.280 |
Why?
|
| Neoplasms, Second Primary | 3 | 2019 | 245 | 0.280 |
Why?
|
| Precision Medicine | 2 | 2020 | 454 | 0.280 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2008 | 113 | 0.280 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2021 | 2474 | 0.280 |
Why?
|
| Genomics | 5 | 2022 | 857 | 0.280 |
Why?
|
| Blood Component Removal | 1 | 2008 | 28 | 0.270 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 3 | 2013 | 24 | 0.270 |
Why?
|
| DNA Mutational Analysis | 4 | 2016 | 547 | 0.270 |
Why?
|
| Gene Expression Profiling | 9 | 2024 | 1535 | 0.260 |
Why?
|
| T-Lymphocytes | 6 | 2023 | 1310 | 0.260 |
Why?
|
| Neoplasm Proteins | 5 | 2018 | 547 | 0.260 |
Why?
|
| Interleukin-2 | 5 | 2013 | 246 | 0.260 |
Why?
|
| Cyclophosphamide | 6 | 2020 | 292 | 0.260 |
Why?
|
| Nuclear Proteins | 4 | 2025 | 750 | 0.260 |
Why?
|
| Genes, ras | 3 | 2019 | 97 | 0.250 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2004 | 135 | 0.250 |
Why?
|
| Haplotypes | 5 | 2019 | 650 | 0.250 |
Why?
|
| Fetal Blood | 3 | 2017 | 95 | 0.240 |
Why?
|
| Infant, Newborn | 4 | 2025 | 2610 | 0.240 |
Why?
|
| Eligibility Determination | 1 | 2026 | 38 | 0.240 |
Why?
|
| Adenine | 2 | 2024 | 92 | 0.230 |
Why?
|
| Trans-Activators | 2 | 2025 | 446 | 0.230 |
Why?
|
| Follow-Up Studies | 21 | 2024 | 3904 | 0.230 |
Why?
|
| Multipotent Stem Cells | 1 | 2025 | 21 | 0.230 |
Why?
|
| Disease Susceptibility | 3 | 2021 | 220 | 0.230 |
Why?
|
| CD52 Antigen | 1 | 2025 | 6 | 0.230 |
Why?
|
| Karyotype | 4 | 2023 | 34 | 0.220 |
Why?
|
| Base Sequence | 8 | 2016 | 2342 | 0.220 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2016 | 463 | 0.220 |
Why?
|
| Genetic Variation | 4 | 2024 | 1422 | 0.220 |
Why?
|
| Imatinib Mesylate | 6 | 2013 | 127 | 0.220 |
Why?
|
| Piperidines | 2 | 2024 | 171 | 0.220 |
Why?
|
| Cohort Studies | 12 | 2025 | 3106 | 0.220 |
Why?
|
| Sarcoma, Myeloid | 2 | 2015 | 14 | 0.220 |
Why?
|
| Survivors | 3 | 2024 | 204 | 0.220 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 556 | 0.220 |
Why?
|
| Graft Rejection | 2 | 2016 | 1126 | 0.220 |
Why?
|
| Immunosuppressive Agents | 5 | 2019 | 995 | 0.220 |
Why?
|
| Medically Uninsured | 1 | 2025 | 67 | 0.220 |
Why?
|
| Tretinoin | 6 | 2018 | 131 | 0.220 |
Why?
|
| Transcription, Genetic | 3 | 2025 | 1192 | 0.210 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2015 | 98 | 0.210 |
Why?
|
| Signal Transduction | 6 | 2024 | 3581 | 0.210 |
Why?
|
| Oxides | 3 | 2014 | 44 | 0.210 |
Why?
|
| Point Mutation | 1 | 2025 | 247 | 0.210 |
Why?
|
| Leukocyte Count | 4 | 2016 | 217 | 0.210 |
Why?
|
| Arsenicals | 3 | 2014 | 49 | 0.210 |
Why?
|
| Sequence Analysis, DNA | 2 | 2019 | 910 | 0.210 |
Why?
|
| Gene Frequency | 3 | 2016 | 703 | 0.200 |
Why?
|
| Oleic Acids | 1 | 2023 | 27 | 0.200 |
Why?
|
| Cell Lineage | 1 | 2025 | 324 | 0.200 |
Why?
|
| Pyrazoles | 3 | 2025 | 161 | 0.200 |
Why?
|
| bcl-X Protein | 1 | 2023 | 55 | 0.200 |
Why?
|
| Neoplasm Staging | 15 | 2025 | 2042 | 0.200 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2023 | 41 | 0.200 |
Why?
|
| Pyridazines | 1 | 2023 | 22 | 0.200 |
Why?
|
| Pyrazines | 1 | 2023 | 94 | 0.200 |
Why?
|
| Guideline Adherence | 1 | 2025 | 245 | 0.200 |
Why?
|
| School Admission Criteria | 1 | 2023 | 31 | 0.200 |
Why?
|
| B-Lymphocytes | 5 | 2025 | 760 | 0.200 |
Why?
|
| Air Pollutants | 1 | 2024 | 109 | 0.190 |
Why?
|
| Cause of Death | 6 | 2020 | 278 | 0.190 |
Why?
|
| DNA Damage | 1 | 2025 | 392 | 0.190 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2009 | 114 | 0.190 |
Why?
|
| Cytogenetic Analysis | 3 | 2014 | 72 | 0.190 |
Why?
|
| Aspartate-Ammonia Ligase | 1 | 2022 | 2 | 0.190 |
Why?
|
| Cancer Survivors | 2 | 2024 | 88 | 0.190 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2018 | 263 | 0.190 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2020 | 111 | 0.180 |
Why?
|
| Hypertriglyceridemia | 1 | 2023 | 72 | 0.180 |
Why?
|
| Translocation, Genetic | 3 | 2016 | 250 | 0.180 |
Why?
|
| Drug Therapy, Combination | 3 | 2021 | 787 | 0.180 |
Why?
|
| Leukemia, B-Cell | 1 | 2022 | 23 | 0.180 |
Why?
|
| Genotype | 5 | 2022 | 1880 | 0.180 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2022 | 23 | 0.180 |
Why?
|
| Patient Care Team | 4 | 2019 | 307 | 0.180 |
Why?
|
| Pilot Projects | 7 | 2020 | 936 | 0.180 |
Why?
|
| Receptors, CXCR5 | 1 | 2021 | 8 | 0.180 |
Why?
|
| Macaca fascicularis | 1 | 2022 | 112 | 0.180 |
Why?
|
| Chemokine CXCL13 | 1 | 2021 | 17 | 0.180 |
Why?
|
| Epigenesis, Genetic | 3 | 2015 | 555 | 0.180 |
Why?
|
| Tissue Donors | 5 | 2013 | 542 | 0.180 |
Why?
|
| Standard of Care | 2 | 2019 | 70 | 0.180 |
Why?
|
| Sarcoma | 1 | 2023 | 224 | 0.180 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2021 | 16 | 0.180 |
Why?
|
| Liver Diseases | 2 | 2022 | 249 | 0.170 |
Why?
|
| Valine | 2 | 2015 | 61 | 0.170 |
Why?
|
| Sex Characteristics | 1 | 2023 | 340 | 0.170 |
Why?
|
| Transplantation Chimera | 5 | 2009 | 84 | 0.170 |
Why?
|
| Phenotype | 2 | 2019 | 2575 | 0.170 |
Why?
|
| Infusions, Intravenous | 6 | 2017 | 420 | 0.170 |
Why?
|
| Mice, SCID | 1 | 2022 | 279 | 0.170 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 640 | 0.170 |
Why?
|
| Comorbidity | 6 | 2018 | 1011 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2022 | 209 | 0.170 |
Why?
|
| DNA, Neoplasm | 6 | 2014 | 272 | 0.170 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 21 | 0.170 |
Why?
|
| Transcription Factors | 6 | 2023 | 1730 | 0.170 |
Why?
|
| Drug Resistance | 3 | 2020 | 234 | 0.170 |
Why?
|
| Repressor Proteins | 2 | 2021 | 447 | 0.160 |
Why?
|
| Biomarkers | 4 | 2022 | 1931 | 0.160 |
Why?
|
| Cell Cycle | 2 | 2014 | 516 | 0.160 |
Why?
|
| Registries | 3 | 2022 | 985 | 0.160 |
Why?
|
| Leukocyte Disorders | 1 | 2000 | 2 | 0.160 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2020 | 38 | 0.160 |
Why?
|
| Drug Synergism | 1 | 2021 | 317 | 0.160 |
Why?
|
| Graft Survival | 9 | 2016 | 942 | 0.160 |
Why?
|
| Patient Participation | 1 | 2022 | 241 | 0.160 |
Why?
|
| DNA-Binding Proteins | 4 | 2016 | 1267 | 0.160 |
Why?
|
| Time Factors | 6 | 2020 | 5561 | 0.150 |
Why?
|
| Colorectal Neoplasms | 9 | 1996 | 1069 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 5 | 2025 | 1096 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 667 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 2 | 2014 | 22 | 0.150 |
Why?
|
| Unrelated Donors | 2 | 2017 | 47 | 0.150 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2019 | 15 | 0.150 |
Why?
|
| Transcriptome | 5 | 2025 | 770 | 0.150 |
Why?
|
| Melanoma | 1 | 2023 | 495 | 0.150 |
Why?
|
| Historically Controlled Study | 1 | 2019 | 6 | 0.150 |
Why?
|
| Atrial Fibrillation | 1 | 2024 | 392 | 0.150 |
Why?
|
| Clinical Studies as Topic | 1 | 2019 | 4 | 0.150 |
Why?
|
| Karyotyping | 3 | 2012 | 224 | 0.150 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2019 | 38 | 0.150 |
Why?
|
| Alleles | 3 | 2024 | 1157 | 0.150 |
Why?
|
| Hematologic Diseases | 3 | 2012 | 78 | 0.150 |
Why?
|
| PAX5 Transcription Factor | 1 | 2019 | 33 | 0.150 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 135 | 0.150 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2021 | 308 | 0.140 |
Why?
|
| Neutropenia | 5 | 2019 | 211 | 0.140 |
Why?
|
| Haploidy | 2 | 2016 | 31 | 0.140 |
Why?
|
| Antigens, CD | 2 | 2018 | 480 | 0.140 |
Why?
|
| Protein Biosynthesis | 1 | 2021 | 398 | 0.140 |
Why?
|
| Postoperative Complications | 14 | 2007 | 2592 | 0.140 |
Why?
|
| Acute Kidney Injury | 2 | 2014 | 341 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 5 | 3 | 1996 | 113 | 0.140 |
Why?
|
| Respiratory Tract Infections | 2 | 2017 | 117 | 0.140 |
Why?
|
| Breast Neoplasms | 3 | 2010 | 3155 | 0.140 |
Why?
|
| Preoperative Care | 3 | 2019 | 417 | 0.140 |
Why?
|
| Antigens, CD19 | 3 | 2024 | 78 | 0.140 |
Why?
|
| Hypertension | 1 | 2024 | 774 | 0.140 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2018 | 20 | 0.140 |
Why?
|
| Cell Differentiation | 6 | 2025 | 1662 | 0.140 |
Why?
|
| Risk | 5 | 2014 | 665 | 0.140 |
Why?
|
| Clinical Protocols | 2 | 2009 | 162 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 171 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 6 | 2003 | 930 | 0.140 |
Why?
|
| Proto-Oncogenes | 2 | 1994 | 61 | 0.140 |
Why?
|
| Proportional Hazards Models | 5 | 2023 | 900 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2012 | 52 | 0.130 |
Why?
|
| Glucocorticoids | 2 | 2020 | 369 | 0.130 |
Why?
|
| Bronchiectasis | 1 | 2017 | 14 | 0.130 |
Why?
|
| Disease Progression | 9 | 2021 | 1559 | 0.130 |
Why?
|
| Cell Cycle Proteins | 1 | 2000 | 412 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 367 | 0.130 |
Why?
|
| Hedgehog Proteins | 1 | 2018 | 107 | 0.130 |
Why?
|
| Potassium | 1 | 2018 | 271 | 0.130 |
Why?
|
| Benzimidazoles | 2 | 2018 | 112 | 0.130 |
Why?
|
| Anticoagulants | 1 | 2020 | 463 | 0.130 |
Why?
|
| Cancer Care Facilities | 1 | 2017 | 36 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2020 | 983 | 0.120 |
Why?
|
| Pancreatitis | 1 | 2017 | 94 | 0.120 |
Why?
|
| Predictive Value of Tests | 5 | 2015 | 1805 | 0.120 |
Why?
|
| Drug Monitoring | 2 | 2008 | 120 | 0.120 |
Why?
|
| Pyrimidinones | 2 | 2019 | 44 | 0.120 |
Why?
|
| Paramyxoviridae | 1 | 2015 | 9 | 0.120 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2018 | 99 | 0.120 |
Why?
|
| Amino Acid Sequence | 3 | 2016 | 2090 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2013 | 80 | 0.120 |
Why?
|
| Stress, Psychological | 2 | 2016 | 347 | 0.120 |
Why?
|
| Filgrastim | 3 | 2015 | 57 | 0.120 |
Why?
|
| Recombinant Proteins | 5 | 2013 | 1006 | 0.120 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2015 | 16 | 0.120 |
Why?
|
| Diverticulitis, Colonic | 4 | 1998 | 12 | 0.120 |
Why?
|
| Hydrazines | 2 | 2020 | 33 | 0.120 |
Why?
|
| Lymphocyte Depletion | 2 | 2017 | 101 | 0.120 |
Why?
|
| Stem Cell Niche | 1 | 2015 | 24 | 0.120 |
Why?
|
| Community-Acquired Infections | 1 | 2015 | 65 | 0.110 |
Why?
|
| Histocompatibility | 3 | 2016 | 66 | 0.110 |
Why?
|
| Pharmacogenomic Testing | 1 | 2016 | 107 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2020 | 591 | 0.110 |
Why?
|
| Patient Safety | 1 | 2017 | 223 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 113 | 0.110 |
Why?
|
| Ganciclovir | 2 | 2006 | 52 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 79 | 0.110 |
Why?
|
| Aminoglycosides | 3 | 2014 | 31 | 0.110 |
Why?
|
| Aftercare | 5 | 1997 | 90 | 0.110 |
Why?
|
| Cyclosporins | 2 | 2013 | 56 | 0.110 |
Why?
|
| Dexamethasone | 2 | 2021 | 350 | 0.110 |
Why?
|
| Paraffin Embedding | 1 | 2014 | 79 | 0.110 |
Why?
|
| Aldehyde Oxidase | 1 | 2014 | 3 | 0.110 |
Why?
|
| Acyclovir | 2 | 2006 | 110 | 0.110 |
Why?
|
| Microarray Analysis | 1 | 2014 | 98 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 1 | 2015 | 173 | 0.100 |
Why?
|
| Intention to Treat Analysis | 3 | 2019 | 81 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2023 | 1134 | 0.100 |
Why?
|
| Palliative Care | 4 | 2019 | 271 | 0.100 |
Why?
|
| Genome-Wide Association Study | 3 | 2021 | 1766 | 0.100 |
Why?
|
| Liposomes | 2 | 2012 | 99 | 0.100 |
Why?
|
| Cytomegalovirus Infections | 2 | 2006 | 155 | 0.100 |
Why?
|
| Neutrophils | 3 | 2021 | 328 | 0.100 |
Why?
|
| Transplantation, Haploidentical | 3 | 2017 | 28 | 0.100 |
Why?
|
| Immunophenotyping | 4 | 2019 | 226 | 0.100 |
Why?
|
| Interleukin-5 | 2 | 1993 | 36 | 0.100 |
Why?
|
| Mercaptopurine | 3 | 2023 | 53 | 0.100 |
Why?
|
| Homeodomain Proteins | 1 | 2016 | 563 | 0.100 |
Why?
|
| Aneuploidy | 1 | 2013 | 61 | 0.100 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2023 | 155 | 0.100 |
Why?
|
| Flow Cytometry | 4 | 2015 | 726 | 0.090 |
Why?
|
| Colon | 4 | 1996 | 542 | 0.090 |
Why?
|
| Medical Oncology | 2 | 2023 | 408 | 0.090 |
Why?
|
| Interleukin-4 | 2 | 1993 | 135 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2009 | 80 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2014 | 740 | 0.090 |
Why?
|
| Genomic Library | 1 | 1992 | 33 | 0.090 |
Why?
|
| Doxorubicin | 2 | 2010 | 290 | 0.090 |
Why?
|
| Busulfan | 2 | 2010 | 42 | 0.090 |
Why?
|
| Obesity | 1 | 2019 | 1030 | 0.090 |
Why?
|
| Administration, Oral | 4 | 2019 | 686 | 0.090 |
Why?
|
| Cytosine | 1 | 2012 | 135 | 0.090 |
Why?
|
| Chimerism | 3 | 2020 | 38 | 0.090 |
Why?
|
| Colony-Forming Units Assay | 2 | 2010 | 39 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2006 | 897 | 0.090 |
Why?
|
| Histocompatibility Testing | 4 | 2017 | 140 | 0.090 |
Why?
|
| Antimitotic Agents | 1 | 2011 | 3 | 0.090 |
Why?
|
| Whole-Body Irradiation | 2 | 2019 | 70 | 0.090 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 1991 | 17 | 0.090 |
Why?
|
| Minority Groups | 2 | 2023 | 154 | 0.090 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2011 | 38 | 0.090 |
Why?
|
| Rectum | 2 | 1995 | 151 | 0.080 |
Why?
|
| Leukocyte Transfusion | 1 | 2010 | 15 | 0.080 |
Why?
|
| Diarrhea | 1 | 2012 | 181 | 0.080 |
Why?
|
| Graft vs Tumor Effect | 1 | 2010 | 26 | 0.080 |
Why?
|
| Janus Kinase 2 | 1 | 2011 | 59 | 0.080 |
Why?
|
| Dioxygenases | 1 | 2011 | 82 | 0.080 |
Why?
|
| Monitoring, Physiologic | 2 | 2006 | 273 | 0.080 |
Why?
|
| Academies and Institutes | 2 | 2021 | 34 | 0.080 |
Why?
|
| Premedication | 2 | 2017 | 58 | 0.080 |
Why?
|
| Gene Expression | 1 | 2014 | 1319 | 0.080 |
Why?
|
| Skin Neoplasms | 2 | 1997 | 621 | 0.080 |
Why?
|
| Harringtonines | 2 | 2008 | 4 | 0.080 |
Why?
|
| Chromatin | 2 | 2024 | 445 | 0.080 |
Why?
|
| Chromosome Deletion | 3 | 2014 | 223 | 0.080 |
Why?
|
| Myeloid Cells | 1 | 2010 | 121 | 0.080 |
Why?
|
| Microsatellite Instability | 1 | 2010 | 64 | 0.080 |
Why?
|
| BK Virus | 1 | 2009 | 24 | 0.080 |
Why?
|
| Polyomavirus Infections | 1 | 2009 | 29 | 0.080 |
Why?
|
| DNA Primers | 3 | 2006 | 548 | 0.080 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 2859 | 0.070 |
Why?
|
| Thrombocytopenia | 3 | 2019 | 187 | 0.070 |
Why?
|
| Hematuria | 1 | 2009 | 50 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 1878 | 0.070 |
Why?
|
| Tumor Virus Infections | 1 | 2009 | 83 | 0.070 |
Why?
|
| Liver | 1 | 2014 | 1231 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2008 | 127 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2012 | 1079 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 182 | 0.070 |
Why?
|
| Prednisone | 2 | 2025 | 252 | 0.070 |
Why?
|
| Diagnosis, Differential | 4 | 2019 | 1613 | 0.070 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2009 | 74 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2009 | 1791 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1957 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2009 | 175 | 0.070 |
Why?
|
| Thiosemicarbazones | 1 | 2008 | 6 | 0.070 |
Why?
|
| Half-Life | 1 | 2008 | 99 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 2039 | 0.070 |
Why?
|
| Methemoglobinemia | 1 | 2008 | 10 | 0.070 |
Why?
|
| Stereoisomerism | 1 | 2008 | 104 | 0.070 |
Why?
|
| Happiness | 1 | 1988 | 12 | 0.070 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2008 | 126 | 0.070 |
Why?
|
| Polycythemia Vera | 2 | 1999 | 23 | 0.070 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 86 | 0.070 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2008 | 61 | 0.070 |
Why?
|
| Microsatellite Repeats | 2 | 2019 | 151 | 0.070 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 206 | 0.070 |
Why?
|
| Genome, Human | 3 | 2022 | 824 | 0.070 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2010 | 74 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2008 | 281 | 0.060 |
Why?
|
| Mycoses | 1 | 2007 | 47 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 3491 | 0.060 |
Why?
|
| Sirolimus | 1 | 2008 | 177 | 0.060 |
Why?
|
| Karnofsky Performance Status | 1 | 2006 | 44 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2009 | 323 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 1981 | 0.060 |
Why?
|
| Cytokines | 2 | 2021 | 871 | 0.060 |
Why?
|
| Allografts | 2 | 2019 | 207 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 403 | 0.060 |
Why?
|
| Leukemia, Hairy Cell | 2 | 2000 | 72 | 0.060 |
Why?
|
| Genes, Neoplasm | 1 | 2006 | 39 | 0.060 |
Why?
|
| Vascular Diseases | 2 | 2018 | 122 | 0.060 |
Why?
|
| Pyridines | 1 | 2008 | 319 | 0.060 |
Why?
|
| Sepharose | 1 | 2005 | 14 | 0.060 |
Why?
|
| Exome | 2 | 2016 | 141 | 0.060 |
Why?
|
| Colectomy | 6 | 1998 | 192 | 0.060 |
Why?
|
| Gallbladder Neoplasms | 1 | 1985 | 23 | 0.060 |
Why?
|
| Microspheres | 1 | 2005 | 105 | 0.060 |
Why?
|
| Spiro Compounds | 1 | 2025 | 30 | 0.060 |
Why?
|
| Antifungal Agents | 2 | 2021 | 126 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 933 | 0.060 |
Why?
|
| Phosphorylation | 3 | 2021 | 1156 | 0.060 |
Why?
|
| Myeloablative Agonists | 2 | 2019 | 38 | 0.060 |
Why?
|
| Antiviral Agents | 2 | 2006 | 504 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 2 | 2016 | 259 | 0.060 |
Why?
|
| Niacinamide | 1 | 2025 | 102 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2024 | 134 | 0.050 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2004 | 7 | 0.050 |
Why?
|
| Interferon-alpha | 2 | 2003 | 194 | 0.050 |
Why?
|
| Quinolones | 1 | 2004 | 57 | 0.050 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2024 | 12 | 0.050 |
Why?
|
| Protein Domains | 1 | 2025 | 164 | 0.050 |
Why?
|
| GTP Phosphohydrolases | 1 | 2024 | 82 | 0.050 |
Why?
|
| Hip Prosthesis | 2 | 1994 | 28 | 0.050 |
Why?
|
| Linoleic Acids, Conjugated | 1 | 2023 | 10 | 0.050 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2023 | 4 | 0.050 |
Why?
|
| Dairy Products | 1 | 2023 | 13 | 0.050 |
Why?
|
| Red Meat | 1 | 2023 | 12 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 299 | 0.050 |
Why?
|
| Tacrolimus | 2 | 2019 | 373 | 0.050 |
Why?
|
| Thymocytes | 1 | 2023 | 31 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2023 | 36 | 0.050 |
Why?
|
| Hip Fractures | 2 | 1994 | 51 | 0.050 |
Why?
|
| Milk | 1 | 2023 | 56 | 0.050 |
Why?
|
| WT1 Proteins | 1 | 2023 | 21 | 0.050 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2023 | 69 | 0.050 |
Why?
|
| Sheep | 1 | 2023 | 250 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2025 | 477 | 0.050 |
Why?
|
| Laboratories | 1 | 2023 | 48 | 0.050 |
Why?
|
| Cyclopentanes | 1 | 2023 | 28 | 0.050 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2023 | 112 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2025 | 528 | 0.050 |
Why?
|
| Molecular Sequence Data | 4 | 2013 | 3040 | 0.050 |
Why?
|
| Cattle | 1 | 2023 | 385 | 0.050 |
Why?
|
| Cell Separation | 2 | 2001 | 205 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2015 | 562 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2025 | 206 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2019 | 297 | 0.050 |
Why?
|
| Quassins | 1 | 2002 | 1 | 0.050 |
Why?
|
| Air Pollution | 1 | 2024 | 107 | 0.050 |
Why?
|
| Prevalence | 2 | 2018 | 1349 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2023 | 283 | 0.050 |
Why?
|
| DNA Methylation | 2 | 2022 | 703 | 0.050 |
Why?
|
| Oral Ulcer | 1 | 2002 | 3 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2023 | 206 | 0.050 |
Why?
|
| Adenocarcinoma | 2 | 1991 | 1192 | 0.050 |
Why?
|
| G1 Phase | 1 | 2002 | 66 | 0.050 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2022 | 32 | 0.050 |
Why?
|
| Pol1 Transcription Initiation Complex Proteins | 1 | 2022 | 1 | 0.050 |
Why?
|
| Actinomycosis | 1 | 2002 | 13 | 0.050 |
Why?
|
| CDX2 Transcription Factor | 1 | 2022 | 7 | 0.050 |
Why?
|
| Sex Factors | 2 | 2020 | 1127 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 178 | 0.050 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2022 | 20 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 111 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2014 | 701 | 0.050 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 308 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2023 | 182 | 0.050 |
Why?
|
| Transaminases | 1 | 2022 | 34 | 0.050 |
Why?
|
| Hospital Departments | 1 | 1982 | 14 | 0.050 |
Why?
|
| Mucin-4 | 1 | 2022 | 7 | 0.050 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2023 | 165 | 0.050 |
Why?
|
| Aging | 2 | 2021 | 766 | 0.050 |
Why?
|
| World Health Organization | 1 | 2022 | 122 | 0.050 |
Why?
|
| Bilirubin | 1 | 2022 | 134 | 0.050 |
Why?
|
| Computers | 1 | 1982 | 109 | 0.050 |
Why?
|
| Aldehyde Reductase | 1 | 2021 | 10 | 0.050 |
Why?
|
| Lymphatic Diseases | 1 | 2002 | 30 | 0.050 |
Why?
|
| CD5 Antigens | 2 | 2000 | 13 | 0.050 |
Why?
|
| Amputation, Traumatic | 1 | 1981 | 9 | 0.050 |
Why?
|
| Finger Injuries | 1 | 1981 | 12 | 0.040 |
Why?
|
| Foot Injuries | 1 | 1981 | 12 | 0.040 |
Why?
|
| Breast | 1 | 2023 | 297 | 0.040 |
Why?
|
| MEDLINE | 1 | 2001 | 8 | 0.040 |
Why?
|
| Lip | 1 | 1981 | 17 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2002 | 152 | 0.040 |
Why?
|
| Hand Injuries | 1 | 1981 | 16 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2022 | 72 | 0.040 |
Why?
|
| CpG Islands | 1 | 2022 | 169 | 0.040 |
Why?
|
| Ketoglutaric Acids | 1 | 2021 | 15 | 0.040 |
Why?
|
| Acetyl-CoA C-Acetyltransferase | 1 | 2021 | 7 | 0.040 |
Why?
|
| Surgery Department, Hospital | 1 | 1982 | 43 | 0.040 |
Why?
|
| Blotting, Southern | 2 | 2003 | 126 | 0.040 |
Why?
|
| NADP | 1 | 2021 | 49 | 0.040 |
Why?
|
| Replantation | 1 | 1981 | 36 | 0.040 |
Why?
|
| Germinal Center | 1 | 2002 | 65 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2014 | 340 | 0.040 |
Why?
|
| Medical Records | 1 | 1982 | 125 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2021 | 416 | 0.040 |
Why?
|
| Scalp | 1 | 1981 | 72 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 83 | 0.040 |
Why?
|
| Amino Acids | 1 | 2022 | 262 | 0.040 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2021 | 9 | 0.040 |
Why?
|
| Killer Cells, Natural | 2 | 2000 | 292 | 0.040 |
Why?
|
| Nose | 1 | 1981 | 96 | 0.040 |
Why?
|
| Ifosfamide | 2 | 2015 | 37 | 0.040 |
Why?
|
| Acetylation | 1 | 2021 | 149 | 0.040 |
Why?
|
| Bone Marrow Diseases | 1 | 2021 | 37 | 0.040 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2000 | 41 | 0.040 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2000 | 20 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 215 | 0.040 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2000 | 37 | 0.040 |
Why?
|
| 3' Untranslated Regions | 1 | 2001 | 100 | 0.040 |
Why?
|
| Papio | 1 | 2001 | 87 | 0.040 |
Why?
|
| Intestinal Perforation | 2 | 1998 | 39 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 306 | 0.040 |
Why?
|
| Antithrombins | 1 | 2020 | 18 | 0.040 |
Why?
|
| Isoantibodies | 1 | 2001 | 127 | 0.040 |
Why?
|
| Length of Stay | 2 | 2018 | 833 | 0.040 |
Why?
|
| Surface Plasmon Resonance | 1 | 2000 | 48 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 294 | 0.040 |
Why?
|
| Mesoderm | 1 | 2001 | 122 | 0.040 |
Why?
|
| Ribosomes | 1 | 2021 | 121 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2001 | 88 | 0.040 |
Why?
|
| Genes, Immunoglobulin | 1 | 2000 | 111 | 0.040 |
Why?
|
| Placebos | 1 | 2020 | 213 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 2 | 2010 | 119 | 0.040 |
Why?
|
| Mentors | 1 | 2021 | 101 | 0.040 |
Why?
|
| Carmustine | 1 | 2020 | 71 | 0.040 |
Why?
|
| Genes, Retinoblastoma | 1 | 2000 | 21 | 0.040 |
Why?
|
| Autografts | 1 | 2020 | 33 | 0.040 |
Why?
|
| Illinois | 2 | 2012 | 530 | 0.040 |
Why?
|
| Bias | 1 | 2020 | 139 | 0.040 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 22 | 0.040 |
Why?
|
| Lysine | 1 | 2021 | 190 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2000 | 109 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 2 | 1997 | 8 | 0.040 |
Why?
|
| Surgical Flaps | 2 | 1995 | 259 | 0.040 |
Why?
|
| Self Report | 1 | 2021 | 328 | 0.040 |
Why?
|
| Cholelithiasis | 2 | 1992 | 36 | 0.040 |
Why?
|
| Benzodiazepines | 1 | 2020 | 71 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2000 | 107 | 0.040 |
Why?
|
| Estradiol | 1 | 2000 | 255 | 0.040 |
Why?
|
| Biosensing Techniques | 1 | 2000 | 81 | 0.040 |
Why?
|
| Logistic Models | 1 | 2023 | 1267 | 0.040 |
Why?
|
| HIV Infections | 1 | 2009 | 974 | 0.040 |
Why?
|
| Diamines | 1 | 2019 | 11 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1999 | 46 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 65 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2022 | 221 | 0.040 |
Why?
|
| Reference Standards | 1 | 2019 | 150 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 1124 | 0.040 |
Why?
|
| Pulmonary Veno-Occlusive Disease | 1 | 2019 | 8 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2019 | 86 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2014 | 796 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2024 | 468 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2015 | 1046 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2022 | 996 | 0.040 |
Why?
|
| Testosterone | 1 | 2000 | 276 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2018 | 34 | 0.040 |
Why?
|
| Interleukin-3 | 2 | 1995 | 39 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2020 | 361 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 322 | 0.040 |
Why?
|
| Chromosomes | 1 | 2019 | 96 | 0.040 |
Why?
|
| Pyridones | 1 | 2019 | 68 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 216 | 0.040 |
Why?
|
| Stem Cells | 1 | 2001 | 394 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2018 | 98 | 0.030 |
Why?
|
| Cladribine | 2 | 2000 | 29 | 0.030 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2018 | 12 | 0.030 |
Why?
|
| Anemia, Sickle Cell | 1 | 2000 | 150 | 0.030 |
Why?
|
| Mental Health | 1 | 2019 | 202 | 0.030 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 16 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2024 | 1275 | 0.030 |
Why?
|
| RNA, Messenger | 4 | 2008 | 2089 | 0.030 |
Why?
|
| Transfection | 2 | 2014 | 908 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2022 | 1827 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2000 | 382 | 0.030 |
Why?
|
| Reoperation | 6 | 1997 | 707 | 0.030 |
Why?
|
| Protein Binding | 1 | 2021 | 1560 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2019 | 348 | 0.030 |
Why?
|
| Lymphocyte Count | 2 | 2013 | 102 | 0.030 |
Why?
|
| Los Angeles | 1 | 2017 | 30 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2017 | 157 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 404 | 0.030 |
Why?
|
| MEF2 Transcription Factors | 1 | 2016 | 10 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2016 | 15 | 0.030 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2016 | 17 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2000 | 681 | 0.030 |
Why?
|
| src Homology Domains | 1 | 2016 | 45 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2016 | 112 | 0.030 |
Why?
|
| Luciferases | 1 | 2016 | 130 | 0.030 |
Why?
|
| Sick Role | 1 | 1996 | 13 | 0.030 |
Why?
|
| Thrombocythemia, Essential | 1 | 1996 | 16 | 0.030 |
Why?
|
| Sigmoid Diseases | 1 | 1996 | 4 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1176 | 0.030 |
Why?
|
| Colostomy | 1 | 1996 | 15 | 0.030 |
Why?
|
| Hydroxyurea | 1 | 1996 | 235 | 0.030 |
Why?
|
| Marital Status | 1 | 2016 | 45 | 0.030 |
Why?
|
| Mesna | 1 | 2015 | 8 | 0.030 |
Why?
|
| U937 Cells | 1 | 2015 | 32 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 38 | 0.030 |
Why?
|
| B-Cell Activating Factor | 1 | 2015 | 8 | 0.030 |
Why?
|
| Osteocalcin | 1 | 2015 | 26 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2017 | 218 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2015 | 38 | 0.030 |
Why?
|
| 5-Methylcytosine | 1 | 2016 | 122 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 579 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2016 | 296 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2010 | 526 | 0.030 |
Why?
|
| Interleukin-7 | 1 | 2015 | 47 | 0.030 |
Why?
|
| Proteins | 1 | 2001 | 816 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2019 | 644 | 0.030 |
Why?
|
| Complementarity Determining Regions | 1 | 2015 | 25 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2882 | 0.030 |
Why?
|
| Educational Status | 1 | 2016 | 202 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2015 | 72 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 694 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2015 | 101 | 0.030 |
Why?
|
| Bone Transplantation | 1 | 1995 | 79 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 154 | 0.030 |
Why?
|
| Zinc Fingers | 1 | 1994 | 60 | 0.030 |
Why?
|
| Microsurgery | 1 | 1995 | 99 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1994 | 47 | 0.030 |
Why?
|
| Biological Availability | 2 | 2005 | 89 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2014 | 30 | 0.030 |
Why?
|
| Patient Compliance | 1 | 1996 | 239 | 0.030 |
Why?
|
| GATA3 Transcription Factor | 1 | 2014 | 52 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1994 | 106 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 2 | 1993 | 41 | 0.030 |
Why?
|
| Chromosome Disorders | 1 | 1994 | 100 | 0.030 |
Why?
|
| Femoral Neck Fractures | 1 | 1994 | 10 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2005 | 67 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2005 | 311 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2016 | 376 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 1993 | 365 | 0.030 |
Why?
|
| Chromosome Banding | 2 | 2010 | 68 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2014 | 40 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2015 | 157 | 0.030 |
Why?
|
| Azepines | 1 | 2014 | 28 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2014 | 53 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 326 | 0.030 |
Why?
|
| Heterografts | 1 | 2014 | 117 | 0.030 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2014 | 28 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2014 | 116 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2014 | 80 | 0.030 |
Why?
|
| Platelet Count | 1 | 2014 | 91 | 0.030 |
Why?
|
| Haploinsufficiency | 1 | 2014 | 69 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1994 | 137 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 170 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2014 | 212 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2014 | 260 | 0.020 |
Why?
|
| Skin | 1 | 1997 | 604 | 0.020 |
Why?
|
| Anxiety | 1 | 2016 | 339 | 0.020 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 33 | 0.020 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 33 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 69 | 0.020 |
Why?
|
| RNA Interference | 1 | 2014 | 385 | 0.020 |
Why?
|
| Dogs | 1 | 2014 | 718 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 1995 | 357 | 0.020 |
Why?
|
| Quality of Life | 2 | 2018 | 1816 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 1995 | 296 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2013 | 68 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 491 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 236 | 0.020 |
Why?
|
| Listeriosis | 1 | 1993 | 90 | 0.020 |
Why?
|
| Thiotepa | 2 | 2003 | 32 | 0.020 |
Why?
|
| Hemodilution | 1 | 1992 | 13 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 1993 | 1080 | 0.020 |
Why?
|
| Colonic Polyps | 1 | 1993 | 137 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2013 | 102 | 0.020 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 1992 | 21 | 0.020 |
Why?
|
| Chromosomes, Fungal | 1 | 1992 | 15 | 0.020 |
Why?
|
| Spermatic Cord | 1 | 1992 | 6 | 0.020 |
Why?
|
| Constipation | 1 | 2012 | 69 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1992 | 152 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 284 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 376 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 32 | 0.020 |
Why?
|
| DNA, Single-Stranded | 1 | 1992 | 97 | 0.020 |
Why?
|
| Anemia | 1 | 2012 | 136 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 1992 | 161 | 0.020 |
Why?
|
| Depression | 1 | 2016 | 560 | 0.020 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1991 | 19 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2012 | 172 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 270 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 1992 | 180 | 0.020 |
Why?
|
| Pneumonia | 1 | 2012 | 196 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2010 | 72 | 0.020 |
Why?
|
| Hernia, Inguinal | 1 | 1992 | 75 | 0.020 |
Why?
|
| Idarubicin | 1 | 2010 | 8 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 1991 | 139 | 0.020 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1991 | 50 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 281 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 431 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1997 | 1319 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 1992 | 620 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 1994 | 829 | 0.020 |
Why?
|
| Family | 1 | 2012 | 331 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2010 | 213 | 0.020 |
Why?
|
| North America | 1 | 2010 | 199 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 2009 | 58 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 632 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2001 | 380 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2009 | 136 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2010 | 179 | 0.020 |
Why?
|
| CD56 Antigen | 2 | 2000 | 18 | 0.020 |
Why?
|
| Clinical Competence | 1 | 1995 | 854 | 0.020 |
Why?
|
| Fever | 1 | 2009 | 131 | 0.020 |
Why?
|
| Fatigue | 1 | 2009 | 185 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 299 | 0.020 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2008 | 20 | 0.020 |
Why?
|
| Myocardial Ischemia | 1 | 2009 | 167 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2005 | 2929 | 0.020 |
Why?
|
| Liver Neoplasms | 2 | 1993 | 790 | 0.020 |
Why?
|
| Word Association Tests | 1 | 1988 | 5 | 0.020 |
Why?
|
| Work | 1 | 1988 | 15 | 0.020 |
Why?
|
| Love | 1 | 1988 | 10 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1990 | 747 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 1991 | 310 | 0.020 |
Why?
|
| Health | 1 | 1988 | 29 | 0.020 |
Why?
|
| Psychological Tests | 1 | 1988 | 91 | 0.020 |
Why?
|
| Social Isolation | 1 | 1988 | 71 | 0.020 |
Why?
|
| Thoracic Neoplasms | 1 | 1987 | 66 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 475 | 0.020 |
Why?
|
| Peptide Elongation Factor 1 | 1 | 2006 | 10 | 0.020 |
Why?
|
| Psychometrics | 1 | 1988 | 340 | 0.020 |
Why?
|
| Cell Extracts | 1 | 2005 | 15 | 0.010 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2005 | 18 | 0.010 |
Why?
|
| Stomatitis | 1 | 2005 | 30 | 0.010 |
Why?
|
| Cholecystectomy | 1 | 1985 | 26 | 0.010 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2006 | 109 | 0.010 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2005 | 48 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2005 | 116 | 0.010 |
Why?
|
| Cholestasis | 1 | 1985 | 44 | 0.010 |
Why?
|
| Anthracyclines | 1 | 2005 | 38 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1997 | 3639 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2005 | 161 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 750 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 364 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 197 | 0.010 |
Why?
|
| Siblings | 1 | 2003 | 109 | 0.010 |
Why?
|
| Viremia | 1 | 2003 | 53 | 0.010 |
Why?
|
| Brucea | 1 | 2002 | 1 | 0.010 |
Why?
|
| Plant Preparations | 1 | 2002 | 20 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 908 | 0.010 |
Why?
|
| Central Nervous System Diseases | 1 | 2003 | 49 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2002 | 89 | 0.010 |
Why?
|
| Germany, West | 1 | 1982 | 3 | 0.010 |
Why?
|
| Splenomegaly | 1 | 2002 | 23 | 0.010 |
Why?
|
| Diagnosis | 1 | 1982 | 18 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 1993 | 2386 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2002 | 149 | 0.010 |
Why?
|
| Phytotherapy | 1 | 2002 | 138 | 0.010 |
Why?
|
| Infusions, Intraosseous | 1 | 2001 | 6 | 0.010 |
Why?
|
| DNA, Recombinant | 1 | 2001 | 62 | 0.010 |
Why?
|
| Selenoproteins | 1 | 2001 | 22 | 0.010 |
Why?
|
| Leukocyte Common Antigens | 1 | 2001 | 51 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2001 | 85 | 0.010 |
Why?
|
| Syndrome | 1 | 2002 | 450 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2001 | 131 | 0.010 |
Why?
|
| Streptavidin | 1 | 2000 | 14 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2002 | 465 | 0.010 |
Why?
|
| Transgenes | 1 | 2001 | 186 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2001 | 145 | 0.010 |
Why?
|
| Nuclear Family | 1 | 2000 | 94 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2001 | 218 | 0.010 |
Why?
|
| Biotinylation | 1 | 2000 | 42 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2000 | 115 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2002 | 234 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2001 | 314 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2000 | 303 | 0.010 |
Why?
|
| Receptors, Interleukin-3 | 1 | 1999 | 3 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 1999 | 9 | 0.010 |
Why?
|
| Carboplatin | 1 | 2001 | 328 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 1999 | 13 | 0.010 |
Why?
|
| Receptors, Erythropoietin | 1 | 1999 | 14 | 0.010 |
Why?
|
| Clone Cells | 1 | 2000 | 223 | 0.010 |
Why?
|
| Heme | 1 | 1999 | 64 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1999 | 87 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1982 | 219 | 0.010 |
Why?
|
| Erythroid Precursor Cells | 1 | 1999 | 33 | 0.010 |
Why?
|
| Erythropoiesis | 1 | 1999 | 53 | 0.010 |
Why?
|
| Rabbits | 1 | 2000 | 639 | 0.010 |
Why?
|
| Erythropoietin | 1 | 1999 | 91 | 0.010 |
Why?
|
| Ligands | 1 | 2000 | 478 | 0.010 |
Why?
|
| Peritonitis | 1 | 1998 | 29 | 0.010 |
Why?
|
| Biopsy | 1 | 2002 | 1208 | 0.010 |
Why?
|
| Receptors, IgG | 1 | 1998 | 68 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2000 | 810 | 0.010 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 1997 | 14 | 0.010 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 1996 | 8 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 267 | 0.010 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1996 | 21 | 0.010 |
Why?
|
| Preleukemia | 1 | 1996 | 10 | 0.010 |
Why?
|
| Chlorambucil | 1 | 1996 | 13 | 0.010 |
Why?
|
| Ribonucleotide Reductases | 1 | 1996 | 6 | 0.010 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1996 | 13 | 0.010 |
Why?
|
| Phlebotomy | 1 | 1996 | 23 | 0.010 |
Why?
|
| Patient Dropouts | 1 | 1996 | 31 | 0.010 |
Why?
|
| Thrombophlebitis | 1 | 1995 | 25 | 0.010 |
Why?
|
| Germany | 1 | 1995 | 80 | 0.010 |
Why?
|
| Surgical Wound Dehiscence | 1 | 1996 | 38 | 0.010 |
Why?
|
| Reference Values | 1 | 1997 | 674 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 1996 | 174 | 0.010 |
Why?
|
| Life Tables | 1 | 1995 | 47 | 0.010 |
Why?
|
| Patient Admission | 1 | 1995 | 122 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 1998 | 483 | 0.010 |
Why?
|
| DNA | 1 | 2001 | 1327 | 0.010 |
Why?
|
| Intestinal Obstruction | 1 | 1996 | 94 | 0.010 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1995 | 111 | 0.010 |
Why?
|
| Lung | 1 | 2001 | 1380 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 1995 | 231 | 0.010 |
Why?
|
| Genes, abl | 1 | 1994 | 12 | 0.010 |
Why?
|
| Elective Surgical Procedures | 1 | 1996 | 162 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1996 | 816 | 0.010 |
Why?
|
| Pressure Ulcer | 1 | 1994 | 44 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1997 | 500 | 0.010 |
Why?
|
| Osteoarthritis, Hip | 1 | 1994 | 22 | 0.010 |
Why?
|
| Fractures, Spontaneous | 1 | 1994 | 17 | 0.010 |
Why?
|
| Colonoscopy | 1 | 1996 | 304 | 0.010 |
Why?
|
| Prosthesis-Related Infections | 1 | 1994 | 60 | 0.010 |
Why?
|
| Interleukin-9 | 1 | 1993 | 3 | 0.010 |
Why?
|
| Cytogenetics | 1 | 1993 | 27 | 0.010 |
Why?
|
| DNA Probes | 1 | 1993 | 76 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 1994 | 171 | 0.010 |
Why?
|
| Wound Healing | 1 | 1995 | 378 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1994 | 599 | 0.010 |
Why?
|
| Stomach Diseases | 1 | 1992 | 19 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 1994 | 310 | 0.010 |
Why?
|
| Duodenal Diseases | 1 | 1992 | 25 | 0.010 |
Why?
|
| Esophageal Diseases | 1 | 1992 | 26 | 0.010 |
Why?
|
| Hemoglobinometry | 1 | 1992 | 8 | 0.010 |
Why?
|
| Osteoporosis | 1 | 1994 | 131 | 0.010 |
Why?
|
| Blood Component Transfusion | 1 | 1992 | 13 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1993 | 477 | 0.010 |
Why?
|
| Fasciotomy | 1 | 1992 | 19 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 1995 | 514 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1994 | 1008 | 0.010 |
Why?
|
| CD11 Antigens | 1 | 1991 | 14 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 1991 | 33 | 0.010 |
Why?
|
| Suture Techniques | 1 | 1992 | 143 | 0.010 |
Why?
|
| Gastrectomy | 1 | 1991 | 70 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1993 | 463 | 0.000 |
Why?
|
| Data Interpretation, Statistical | 1 | 1990 | 312 | 0.000 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1987 | 156 | 0.000 |
Why?
|